Press Releases

L’Amministratore Delegato di Eni, Claudio Descalzi, e il Presidente esecutivo di Dompé farmaceutici, Sergio Dompé hanno siglato oggi una Lettera d’Intenti (LOI) per avviare attività congiunte di ricerca e sviluppo riguardanti la salute delle persone e delle comunità nei territori in cui Eni opera e più in generale tematiche di salute globale.

Dompé farmaceutici S.p.A. and FarmaMondo Group announced they have extended their agreement whereby FarmaMondo Group becomes Dompé’s distribution partner for Oxervate (cenegermin) in additional selected countries. 

MA, Ph.D and post-doc candidates at US universities to be supported with 1 million USD Applications on www.dompefoundation.org | Deadline December 31st, 2023

Unprecedented comprehension of the interaction between Spike and the Human Estrogen Receptor Alfa provides insights for a new generation of anti SARS-CoV-2 and pan-Coronavirus vaccines

A team of US and European researchers have released new findings in Science Advances showing how the SARS-CoV-2 Spike (S)-protein interacts with human Estrogen Receptor Alpha (ERα) in lung tissue. Data released as pre-print on bioRxiv reveals the interaction of SARS-CoV-2 (S) Spike proteins with ERα may increase the pro-coagulation activity of endothelial cells, enhancing the risk of thrombosis and shedding new light on the pathogenic mechanisms underlying SARS-CoV-2 infection and on its sex-specific differences. Additional data by the same research groups highlights the mechanism underlying some rare vaccine-associated coagulopathies, which may be prevented by small changes in the Spike sequence used to produce currently available vaccines.

Dompé farmaceutici is the first private company to sign an agreement for the use of the computing resources of the Leonardo supercomputer, the fourth most powerful in the world, inaugurated today at the Bologna Technopole and managed by the Cineca Consortium.

Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants. Raloxifene was identified as a potential COVID-19 treatment by Exscalate4CoV consortium, a multidisciplinary European center of excellence created with the aim to fighting coronavirus by combining the best supercomputing resources and artificial intelligence with state of the art experimental facilities up through clinical validation.New digital open tools for researches are now being developed with the support of the European High Performance Computing Joint Undertaking to further accelerate the drug discovery process.

In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia.Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy